Press release




Biophy(s Powers Innova(on in Obesity, Muscle Health,
and Longevity at BIO Interna(onal 2025

Paris, France, Cambridge (Massachuse5s, USA), July 3, 2025 – 07h00 — BiophyGs, a pioneering force
in the development of transformaGve therapies for obesity, sarcopenia, and longevity, is proud to
announce its successful parGcipaGon at the BIO InternaGonal ConvenGon 2025, the world’s largest and
most comprehensive biotechnology event. Hosted at the Boston ConvenGon & ExhibiGon Center from
June 16-19, 2025, the convenGon gathered 20,000 industry leaders from across the globe, providing an
unparalleled plaXorm for collaboraGon, partnership, and scienGfic exchange.

On this occasion, BiophyGs engaged with global biopharma execuGves, investors, and research
insGtuGons, highlighGng its robust pipeline and innovaGve approaches to addressing some of the most
pressing health challenges of our Gme. The company’s proprietary therapies—targeGng obesity, age-
related muscle wasGng (sarcopenia), and the biological mechanisms of aging—are at the forefront of a
new era in precision medicine and healthy longevity.

Key Highlights from BIO 2025:

• Obesity InnovaGon: BiophyGs presented its latest advancements on its IND readiness Phase 2
trial, with BIO101 that go beyond tradiGonal weight loss soluGons. The Company’s research is
focused on next-generaGon pharmacotherapies, designed to restore mobility for paGents
suffering from obesity.

• Sarcopenia Breakthroughs: BiophyGs has the most advanced candidate in age-related
sarcopenia aaer the promising results of Phase 2. BIO101 with a strong safety profile has
demonstrated potenGal to improve quality of life for millions worldwide. The Company is
speeding up to start the Phase 3.

• Longevity Leadership: By targeGng the root causes of aging, BiophyGs is pioneering therapies
that not only extend lifespan but also enhance healthspan—the period of life lived in good
health. The Company’s research focuses idenGfying new therapeuGc targets and new candidates
by integraGng new technologies and leverage AI.

Post-Conference Momentum

Following the convenGon, BiophyGs is acGvely pursuing strategic partnerships, licensing opportuniGes,
and collaboraGons to accelerate the development and global commercializaGon of its therapies. The
Company’s presence at BIO 2025 has already catalyzed new discussions with leading pharmaceuGcal
firms, investors, and academic insGtuGons, reinforcing its commitment to delivering life-changing
treatments to paGents around the world.
Press release


About BIOPHYTIS


BiophyGs SA is a clinical-stage biotechnology company focused on developing drug candidates for age-
related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in
development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders
(obesity, Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in
Cambridge, Massachuse5s, USA, and Brazil. The Company’s ordinary shares are listed on Euronext
Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC
market (BPTSY - US 09076G401). For more informaGon, visit www.biophyGs.com.



Disclaimer

This press release contains forward-looking statements. Forward-looking statements include all
statements that are not historical facts. In some cases, you can idenGfy these forward-looking
statements by the use of words such as "outlook," "believes," "expects," "potenGal," "conGnues," "may,"
"will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "esGmates," "anGcipates" or
the negaGve version of these words or other comparable words. Such forward-looking statements are
based on assumpGons that BiophyGs considers to be reasonable. However, there can be no assurance
that the statements contained in such forward-looking statements will be verified, which are subject to
various risks and uncertainGes. The forward- looking statements contained in this press release are also
subject to risks not yet known to BiophyGs or not currently considered material by BiophyGs. Accordingly,
there are or will be important factors that could cause actual outcomes or results to differ materially
from those indicated in these statements. Please also refer to the "Risk and uncertainGes the Company
is to face" secGon from the Company’s 2023 Financial Report available on BIOPHYTIS website
(www.biophyGs.com) and as exposed in the "Risk Factors" secGon of form 20-F as well as other forms
filed with the SEC (SecuriGes and Exchange Commission, USA). We undertake no obligaGon to publicly
update or review any forward-looking statement, whether because of new informaGon or otherwise,
except as required by law.



BiophyGs Contacts

Investor Relations
Investors@biophytis.com

US Investors
Pascal Nigen – Alpha Bronze
pnigen@alphabronzellc.com

Media contacts
Antoine Denry: antoine.denry@taddeo.fr – +33 6 18 07 83 27
Inès de Mandiargues: ines.demandiargues@taddeo.fr - +33 6 16 16 51 78